TORONTO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce the positive results of its smoldering multiple myeloma proof of concept study, recently published within the proceedings of the American Society of Hematology (ASH) annual meeting 2020.
In this published study, TeloView®’s quantitative and spatial analysis of 6 key parameters of telomeres was conducted on a total of 26 patients that were diagnosed with smoldering multiple myeloma. The cohort included 21 stable patients who remained at the smoldering stage for over 5 years and 5 high-risk patients that progressed to the active multiple myeloma stage within 2 years from point of diagnosis. A high level of statistical significance was observed across all of the 6 parameters measured by TeloView®, and the analysis distinguished between the group of patients that remained stable with smoldering multiple myeloma from the group that progressed to active multiple myeloma in 26 out of the 26 patients-cohort.
The study was conducted blindly on the diagnostic specimens suggesting the capability of TeloView® analysis to stratify smoldering multiple myeloma patients at the point of diagnosis. These results have the potential to guide evidence-based decisions to treat smoldering multiple myeloma patients with a high risk of progression, addressing a critical unmet clinical need in the management of multiple myeloma.
Telo Genomics is conducting further studies on expanded cohorts of patients to further validate the results obtained from this proof of concept study, and to confirm the utility of its TeloView® technology to predict the progression of smoldering multiple myeloma in patients.
The full text of the abstract is available at the November 2020 supplemental issue of the scientific journal “Blood” –
Multiple myeloma is a highly challenging and deadly blood cancer that forms in plasma cells, a type of white blood cell. Symptoms include bone pain, frequent infections, fatigue, and weight loss. Smoldering multiple myeloma is an asymptomatic precursor to active multiple myeloma. There is an increasing industry trend towards identifying high-risk smoldering multiple myeloma patients to initiate early treatment and achieve better clinical outcomes (Boutros M. et al 2020). The annual incidence of multiple myeloma is approximately 32,000 newly diagnosed cases in the USA per year, with approximately 250,000 cases of smoldering multiple myeloma, of which 10-15% of smoldering multiple myeloma patients progress to active multiple myeloma every year.
“These published results are encouraging for TeloView® and indicates that it has the potential to fill an important unmet diagnostic/prognostic need for smoldering multiple myeloma,” said Guido Baechler, TELO’s Chairman, “We look forward to further validation in our additional clinical studies, and we see now the potential for establishing future strategic partnerships to accelerate the transition of TeloView® tests towards commercialization.”
Reference:
Boutros M. et al Genomic Profiling of Smouldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. J Clin Oncol. 2020 Jul 20;38(21):2380-2389
The American Society of Haematology represents healthcare professionals involved in the management of blood disorders including cancer. The ASH annual meeting is one of the top clinical international meetings focused on blood cancers. ASH attracts more than 30,000 attendees, predominantly clinicians.
About Telo Genomics
Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team’s considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease-associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in over 150 peer reviewed publications and in 25 clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer’s disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer. For more information please visit www.telodx.com.
For further information, please contact:
Hugh Rogers, Director
416-673-8487
info@telodx.com
MaRS Centre, South Tower, 101 College Street, Suite 200, Toronto, ON, M5G 1L7
www.telodx.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “intends”, “will”, or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements regarding the clinical efficacy of products, commercial viability of products, use of proceeds, and the ability of the TeloViewTM platform to deliver personalized medicine resulting in better treatments and outcomes are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.